跳至主要内容
临床试验/NCT00038194
NCT00038194已完成1 期

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2001年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
28
试验地点
1

研究概览

简要总结

The goal of this clinical research study is to find the highest safe dose of docetaxel in combination with Gleevec (imatinib mesylate) that can be given to men with advanced androgen-independent metastatic prostate cancer that involves bone. Docetaxel is a commercial chemotherapy which interferes with the cancer cell ability to divide and grow.

详细描述

OBJECTIVES:

  1. To define the maximum tolerated dose of weekly docetaxel in combination with fixed-dose oral STI571 in adult men with metastatic androgen-independent prostate cancer (AIPC).
  2. To determine the qualitative and quantitative toxicity of the combination of oral STI571 and docetaxel.
  3. Evaluate PSA modulation with STI571 alone at thirty days in patients with AIPC.
  4. Obtain a preliminary estimate of the response rate in AIPC to the combination of STI571 and docetaxel.
  5. Obtain tissue for correlative science studies (these are optional studies).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Imatinib + Docetaxel

Experimental

干预措施: imatinib mesylate (Drug)

Imatinib + Docetaxel

Experimental

干预措施: docetaxel (Drug)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Phase I Trial of Fixed Dose STI571 (Imatinib... | 临床试验